Amedisys Stock Forecast, Price & News

Today's Range N/A
50-Day Range
MA: $264.97
52-Week Range N/A
Volume163,691 shs
Average Volume198,250 shs
Market Capitalization$9.29 billion
P/E Ratio56.71
Dividend YieldN/A
Amedisys, Inc., together with its subsidiaries, provides healthcare services in the United States. It operates through three segments: Home Health, Hospice, and Personal Care. The Home Health segment offers a range of services in the homes of individuals for the recovery of patients from surgery, chronic disability, or terminal illness, as well as prevents avoidable hospital readmissions through its skilled nurses; rehabilitation therapists specialized in physical, speech, and occupational therapy; and social workers and aides for assisting its patients. The Hospice segment offers services that is designed to provide comfort and support for those who are dealing with a terminal illness, including cancer, heart disease, pulmonary disease, or Alzheimer's. The Personal Care segment provides assistance for patients with the activities of daily living. As of December 31, 2020, the company owned and operated 320 home health care centers, 180 hospice care centers, and 14 personal-care care centers in 39 states within the United States and the District of Columbia. Amedisys, Inc. was incorporated in 1982 and is headquartered in Baton Rouge, Louisiana.
Amedisys logo

Industry, Sector and Symbol

Industry Home health care services
Sub-IndustryHealth Care Services
Current SymbolNASDAQ:AMED
Year Founded1982



Sales & Book Value

Annual Sales$1.96 billion
Book Value$19.89 per share


Net Income$126.83 million


Market Cap$9.29 billion
Next Earnings Date4/28/2021 (Confirmed)


Returns At Amedisys (NASDAQ:AMED) Are On The Way Up
April 1, 2021 |
See More Headlines


Overall MarketRank

1.57 out of 5 stars

Medical Sector

947th out of 2,024 stocks

Home Health Care Services Industry

6th out of 9 stocks

Analyst Opinion: 3.4Community Rank: 2.2Dividend Strength: 0.0Insider Behavior: 1.7Valuation: 0.6 5 -4 -3 -2 -1 -
30 days | 90 days | 365 days | Advanced Chart

Receive AMED News and Ratings via Email

Sign-up to receive the latest news and ratings for AMED and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles

Amedisys (NASDAQ:AMED) Frequently Asked Questions

Is Amedisys a buy right now?

12 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Amedisys in the last year. There are currently 3 hold ratings and 9 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" Amedisys stock.
View analyst ratings for Amedisys
or view top-rated stocks.

What stocks does MarketBeat like better than Amedisys?

Wall Street analysts have given Amedisys a "Buy" rating, but there may be better short-term opportunities in the market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new trading ideas, but Amedisys wasn't one of them. MarketBeat thinks these five stocks may be even better buys.
View MarketBeat's top stock picks here.

Are investors shorting Amedisys?

Amedisys saw a increase in short interest in the month of March. As of March 15th, there was short interest totaling 531,700 shares, an increase of 40.6% from the February 28th total of 378,100 shares. Based on an average daily volume of 196,500 shares, the short-interest ratio is presently 2.7 days.
View Amedisys' Short Interest

When is Amedisys' next earnings date?

Amedisys is scheduled to release its next quarterly earnings announcement on Wednesday, April 28th 2021.
View our earnings forecast for Amedisys

How can I listen to Amedisys' earnings call?

Amedisys will be holding an earnings conference call on Wednesday, April 28th at 12:00 AM Eastern. Interested parties can register for or listen to the call using this link or dial in at Not Available.

How were Amedisys' earnings last quarter?

Amedisys, Inc. (NASDAQ:AMED) issued its quarterly earnings results on Tuesday, February, 23rd. The health services provider reported $1.49 earnings per share for the quarter, topping the Thomson Reuters' consensus estimate of $1.47 by $0.02. The health services provider had revenue of $550.71 million for the quarter, compared to the consensus estimate of $551.91 million. Amedisys had a net margin of 8.22% and a trailing twelve-month return on equity of 26.41%. During the same period in the previous year, the company posted $0.94 EPS.
View Amedisys' earnings history

What guidance has Amedisys issued on next quarter's earnings?

Amedisys issued an update on its FY21 earnings guidance on Wednesday, February, 24th. The company provided earnings per share guidance of $6.25-6.47 for the period, compared to the Thomson Reuters consensus earnings per share estimate of $6.33. The company issued revenue guidance of $2.275-2.315 billion, compared to the consensus revenue estimate of $2.31 billion.

What price target have analysts set for AMED?

12 brokerages have issued 12-month price targets for Amedisys' shares. Their forecasts range from $190.00 to $340.00. On average, they anticipate Amedisys' share price to reach $274.46 in the next twelve months.
View analysts' price targets for Amedisys
or view top-rated stocks among Wall Street analysts.

Who are Amedisys' key executives?

Amedisys' management team includes the following people:
  • Mr. Paul Berthold Kusserow, Chairman & CEO (Age 60, Pay $1.33M)
  • Mr. Christopher T. Gerard, Pres & COO (Age 54, Pay $1.34M)
  • Mr. Scott G. Ginn, Exec. VP & CFO (Age 52, Pay $1.22M)
  • Mr. David L. Kemmerly, Chief Legal & Gov. Affairs Officer (Age 58, Pay $851.77k)
  • Ms. Sharon Brunecz, Chief HR Officer (Age 54, Pay $844.58k)
  • Mr. Pete Hartley, CTO & Sr. VP of Bus. Operations Systems
  • Mr. Michael P. North, Chief Information Officer (Age 56)
  • Mr. Denise Bohnert, Chief Compliance Officer (Age 43)
  • Kendra Kimmons, VP of Marketing & Communications
  • Mr. John Nugent, Chief Acquisitions Officer

What is Paul B. Kusserow's approval rating as Amedisys' CEO?

297 employees have rated Amedisys CEO Paul B. Kusserow on Paul B. Kusserow has an approval rating of 79% among Amedisys' employees.

Who are some of Amedisys' key competitors?

What other stocks do shareholders of Amedisys own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Amedisys investors own include NVIDIA (NVDA), Alibaba Group (BABA), Johnson & Johnson (JNJ), Pfizer (PFE), Adobe (ADBE), Intel (INTC), QUALCOMM (QCOM), Broadcom (AVGO), Cisco Systems (CSCO) and The Home Depot (HD).

What is Amedisys' stock symbol?

Amedisys trades on the NASDAQ under the ticker symbol "AMED."

Who are Amedisys' major shareholders?

Amedisys' stock is owned by a number of institutional and retail investors. Top institutional investors include Retirement Systems of Alabama (0.24%), Louisiana State Employees Retirement System (0.03%), Fulcrum Equity Management (0.02%), HMS Capital Management LLC (0.02%), State of Alaska Department of Revenue (0.02%) and Shilanski & Associates Inc. (0.01%). Company insiders that own Amedisys stock include Bruce D Perkins, Christopher Gerard, David B Pearce, David L Kemmerly, Denise M Bohnert, Donald A Washburn, Jake L Netterville, Jeffrey A Rideout, Julie D Klapstein, Michael Paul North, Scott G Ginn, Sharon Brunecz, Teresa L Kline and Vickie L Capps.
View institutional ownership trends for Amedisys

Which institutional investors are selling Amedisys stock?

AMED stock was sold by a variety of institutional investors in the last quarter, including Calamos Advisors LLC, State of Alaska Department of Revenue, Shilanski & Associates Inc., Pacer Advisors Inc., and First Citizens Bank & Trust Co.. Company insiders that have sold Amedisys company stock in the last year include Christopher Gerard, David L Kemmerly, Denise M Bohnert, Michael Paul North, Scott G Ginn, and Sharon Brunecz.
View insider buying and selling activity for Amedisys
or view top insider-selling stocks.

Which institutional investors are buying Amedisys stock?

AMED stock was acquired by a variety of institutional investors in the last quarter, including Fulcrum Equity Management, Hanlon Investment Management Inc., TrimTabs Asset Management LLC, FDx Advisors Inc., HMS Capital Management LLC, Paragon Advisors LLC, Louisiana State Employees Retirement System, and Veracity Capital LLC. Company insiders that have bought Amedisys stock in the last two years include Bruce D Perkins, Teresa L Kline, and Vickie L Capps.
View insider buying and selling activity for Amedisys
or or view top insider-buying stocks.

How do I buy shares of Amedisys?

Shares of AMED can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

How much money does Amedisys make?

Amedisys has a market capitalization of $0.00 and generates $1.96 billion in revenue each year. The health services provider earns $126.83 million in net income (profit) each year or $4.40 on an earnings per share basis.

How many employees does Amedisys have?

Amedisys employs 21,000 workers across the globe.

When was Amedisys founded?

Amedisys was founded in 1982.

What is Amedisys' official website?

The official website for Amedisys is

Where are Amedisys' headquarters?

Amedisys is headquartered at 3854 AMERICAN WAY SUITE A, BATON ROUGE LA, 70816.

How can I contact Amedisys?

Amedisys' mailing address is 3854 AMERICAN WAY SUITE A, BATON ROUGE LA, 70816. The health services provider can be reached via phone at 225-292-2031 or via email at [email protected]

This page was last updated on 4/18/2021 by Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security. Learn more.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research. As a bonus to opt-ing into our email newsletters, you will also get a free subscription to the Liberty Through Wealth e-newsletter. You can opt out at any time.